These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29167095)

  • 81. Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.
    Kantarjian H; Mathisen MS; Lipton JH
    JAMA Oncol; 2015 Sep; 1(6):729-30. PubMed ID: 26182331
    [No Abstract]   [Full Text] [Related]  

  • 82. Patient access schemes for high-cost cancer medicines.
    Williamson S
    Lancet Oncol; 2010 Feb; 11(2):111-2. PubMed ID: 20152762
    [No Abstract]   [Full Text] [Related]  

  • 83. The impact of technology on health care cost and policy development.
    Wallner PE; Konski A
    Semin Radiat Oncol; 2008 Jul; 18(3):194-200. PubMed ID: 18513629
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer.
    Davies BJ; Hwang TJ; Kesselheim AS
    N Engl J Med; 2017 Apr; 376(15):1401-1403. PubMed ID: 28402764
    [No Abstract]   [Full Text] [Related]  

  • 85. Health Technology Assessment in the UK.
    Raftery J; Powell J
    Lancet; 2013 Oct; 382(9900):1278-85. PubMed ID: 24120204
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cancer drugs run short in the Gaza Strip.
    Devi S
    Lancet Oncol; 2018 Oct; 19(10):1284. PubMed ID: 30177498
    [No Abstract]   [Full Text] [Related]  

  • 87. Clinical equipment replacement plan puts budget spotlight on bedside technologies.
    Williams JS
    Biomed Instrum Technol; 2010; 44(6):478-81. PubMed ID: 21142512
    [No Abstract]   [Full Text] [Related]  

  • 88. Oral oncolytics: Part 2--legislation targeting cost & access, and other initiatives to reduce costs.
    Mancini R; McBride A; Kruczynski M
    Oncology (Williston Park); 2013 Sep; 27(9):865-6, 871. PubMed ID: 24282981
    [No Abstract]   [Full Text] [Related]  

  • 89. A thematic analysis of the strengths and weaknesses of manufacturers' submissions to the NICE Single Technology Assessment (STA) process.
    Carroll C; Kaltenthaler E; FitzGerald P; Boland A; Dickson R
    Health Policy; 2011 Oct; 102(2-3):136-44. PubMed ID: 21763025
    [TBL] [Abstract][Full Text] [Related]  

  • 90. How to assess new devices.
    McConnell EA
    Nurs Manage; 1998 Jun; 29(6):59. PubMed ID: 9807435
    [No Abstract]   [Full Text] [Related]  

  • 91. Sterile supplies for the primary care doctor.
    Newsom RA
    Sterile World; 1982 Oct; 4(5):13. PubMed ID: 10261334
    [No Abstract]   [Full Text] [Related]  

  • 92. Flight disruption. Volcanic ash cloud affects cancer drug supplies.
    Health Serv J; 2010 Apr; 120(6203):7. PubMed ID: 20509198
    [No Abstract]   [Full Text] [Related]  

  • 93. A world of innovators.
    Oldham J
    Health Serv J; 2012 Sep; 122(6319):22-3. PubMed ID: 23074878
    [No Abstract]   [Full Text] [Related]  

  • 94. Creating access to health technologies in poor countries.
    Frost LJ; Reich MR
    Health Aff (Millwood); 2009; 28(4):962-73. PubMed ID: 19597194
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Health technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the United States take notice?
    Dranitsaris G; Papadopoulos G
    Appl Health Econ Health Policy; 2015 Jun; 13(3):291-302. PubMed ID: 25274258
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Purchasing. The gang way.
    Lee P
    Health Serv J; 2005 Jun; 115(5959):40. PubMed ID: 15981835
    [No Abstract]   [Full Text] [Related]  

  • 97. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?
    Mason A; Drummond M; Ramsey S; Campbell J; Raisch D
    J Clin Oncol; 2010 Jul; 28(20):3234-8. PubMed ID: 20498408
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Editor's Choice: StatBite drug shortages, 2001-2010.
    U.S. Food and Drug Administration
    J Natl Cancer Inst; 2011 Jun; 103(12):915. PubMed ID: 21693753
    [No Abstract]   [Full Text] [Related]  

  • 99. Health technology assessment from a Canadian device industry perspective.
    Ferrusi IL; Ames D; Lim ME; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):353-9. PubMed ID: 19394576
    [TBL] [Abstract][Full Text] [Related]  

  • 100. At last, NICE to take over the Cancer Drugs Fund.
    Timmins N
    BMJ; 2016 Mar; 352():i1324. PubMed ID: 26951838
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.